TriSalus Life Sciences Valuation
Is TLSI undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TLSI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TLSI ($3.67) is trading above our estimate of fair value ($3.13)
Significantly Below Fair Value: TLSI is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TLSI?
Key metric: As TLSI is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is TLSI's PS Ratio? | |
|---|---|
| PS Ratio | 4.2x |
| Sales | US$26.89m |
| Market Cap | US$119.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.9x |
| Enterprise Value/EBITDA | -2.9x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does TLSI's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 8.5x | ||
FENC Fennec Pharmaceuticals | 2.2x | 27.9% | US$109.5m |
ANL Adlai Nortye | 21.8x | 65.7% | US$115.1m |
ELUT Elutia | 5x | 45.5% | US$121.3m |
GBIO Generation Bio | 5.1x | -14.7% | US$102.9m |
TLSI TriSalus Life Sciences | 4.2x | 33.6% | US$119.8m |
Price-To-Sales vs Peers: TLSI is good value based on its Price-To-Sales Ratio (4.2x) compared to the peer average (8.5x).
Price to Sales Ratio vs Industry
How does TLSI's PS Ratio compare vs other companies in the US Biotechs Industry?
| 145 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 10.3x | 20.8% | |
TLSI TriSalus Life Sciences | 4.2x | 33.6% | US$119.83m |
AMGN Amgen | 4.6x | 2.4% | US$152.45b |
GILD Gilead Sciences | 3.9x | 2.4% | US$110.17b |
| 145 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 10.3x | 26.7% | |
TLSI TriSalus Life Sciences | 4.2x | 66.7% | US$119.83m |
Price-To-Sales vs Industry: TLSI is good value based on its Price-To-Sales Ratio (4.2x) compared to the US Biotechs industry average (10.3x).
Price to Sales Ratio vs Fair Ratio
What is TLSI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 4.2x |
| Fair PS Ratio | 6.2x |
Price-To-Sales vs Fair Ratio: TLSI is good value based on its Price-To-Sales Ratio (4.2x) compared to the estimated Fair Price-To-Sales Ratio (6.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$3.67 | US$11.92 +224.7% | 16.5% | US$16.00 | US$10.00 | n/a | 6 |
| Nov ’25 | US$4.01 | US$12.30 +206.7% | 16.6% | US$16.00 | US$10.00 | n/a | 5 |
| Oct ’25 | US$4.32 | US$12.25 +183.6% | 18.6% | US$16.00 | US$10.00 | n/a | 4 |
| Sep ’25 | US$5.25 | US$13.00 +147.6% | 16.6% | US$16.00 | US$11.00 | n/a | 3 |
| Aug ’25 | US$5.80 | US$14.67 +152.9% | 12.9% | US$16.00 | US$12.00 | n/a | 3 |
| Jul ’25 | US$5.33 | US$14.67 +175.2% | 12.9% | US$16.00 | US$12.00 | n/a | 3 |
| Jun ’25 | US$7.16 | US$14.67 +104.8% | 12.9% | US$16.00 | US$12.00 | n/a | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Collegium Pharmaceutical
US$954.0m
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$29.22
7D
-9.2%
1Y
14.2%
ANI Pharmaceuticals
US$1.1b
A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.
ANIP
US$55.25
7D
-10.5%
1Y
7.7%
Teva Pharmaceutical Industries
US$18.6b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.49
7D
-5.1%
1Y
74.5%